Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866839 · ClinicalTrials.gov registry record · Phase 1
Preventing Stem Cell Transplant Complications With a Blood Separator Machine
A Phase 1 study of Lymphoma, Non-Hodgkin and MDS (Myelodysplastic Syndrome), sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT01866839 is a Phase 1 study of Lymphoma, Non-Hodgkin and MDS (Myelodysplastic Syndrome) that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 41 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01866839, a Phase 1 study of Lymphoma, Non-Hodgkin and MDS (Myelodysplastic Syndrome), has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Researchers are working to make stem cell transplant procedures safer and more effective. One complication of transplants is graft-versus-host disease (GVHD). This complication happens when certain white blood cells from the donor attack the recipient's own body. Researchers want to test a blood separator machine that may help remove more of the donor's white blood cells before transplant. They will study donors and recipients during stem cell transplant to see how well this process can prevent GVHD and other complications. Objectives: \- To see if a new blood separator machine can improve outcomes of stem cell transplants. Eligibility: * Individuals between 10 and 75 years of age who are having a stem cell transplant for leukemia or other blood-related cancers. * Donors for the stem cell transplant. Design: * Recipients and donors will be screened with a physical exam and medical history. * Donors will have two blood collection procedures. The first will collect only white blood cells, and return the rest of the blood. After the first collection, participants will have filgrastim injections to help their stem cells enter their blood. Then, they will have a second blood collection for the stem cells. * Recipients will have radiation and chemotherapy to prepare for the stem cell transplant. They will then have the stem cell transplant with the donor cells that have been treated with the blood separator machine. * Recipients will be monitored closely after the procedure. They may receive some of their donor's white blood cells if needed to fight serious infections. * Recipients will have the regular standard of care after their transplant. Blood samples will be taken and any side effects will be monitored and treated.
Conditions Studied
Interventions
- DEVICE Graft Manipulation (CD34+ Selection)
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-05-29 |
| Est. Completion | 2018-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01866839
The ClinicalTrials.gov registry entry for NCT01866839 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (90% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which Graft Manipulation (CD34+ Selection) is the first listed.
NCT01866839 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01866839 about?
NCT01866839 is a clinical study titled "Preventing Stem Cell Transplant Complications With a Blood Separator Machine". Background: \- Researchers are working to make stem cell transplant procedures safer and more effective. One complication of transplants is graft-versus-host disease (GVHD). This complication happens when certain white blood cells from the donor attack the recipient's own body. Researchers want to ...
What is the current status of trial NCT01866839?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2013-05-29. Estimated completion is 2018-06-28.
What conditions does trial NCT01866839 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, AML (Acute Myelogenous Leukemia), ALL (Acute B-Lymphoblastic Leukemia).
What interventions are being tested in trial NCT01866839?
The interventions under investigation include: Graft Manipulation (CD34+ Selection) (DEVICE).
Who is sponsoring clinical trial NCT01866839?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01866839 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.